Enrollment Begins For Study Of MBP8298 In SPMS
Submitted by art on Wed, 2007-06-27 07:03.
Enrollment has begun for a study testing the safety and effectiveness of the experimental drug MBP8298 (BioMS Medical Corp.) in 510 people with secondary-progressive multiple sclerosis. Up to 60 sites nationwide will be enrolling patients by September. This drug is administered intravenously (into the vein) every 6 months.
Trial enrollment info here.